258P - Prognostic factors in early-stage triple negative breast cancer (TNBC): the limits of clinical and pathological features
|Date||01 October 2012|
|Event||ESMO Congress 2012|
|Session||Poster presentation III|
|Topics|| Breast Cancer, Early Stage
N. Pecuchet1, M. Le Frère Belda2, T. Popovski3, S. Haouas1, F. Chamming'S4, F. Lécuru5, S. Oudard6, J. Medioni1
Triple negative breast cancer (TNBC) patients (pts) is an heterogeneous population regarding prognostic. Therefore, clinical and histological features were evaluated in a large monocenter cohort of patients treated for localized TNBC to identify good-prognostic TNBC.Methods
All consecutive early-stage TNBC (ER 0%, PR 0%, HER2 neg) patients treated at European Georges Pompidou Hospital, Paris, France, between 2000 and 2011 were included. Records were reviewed for demographic, clinical and pathological data. Prognostic factors were determined using univariate and multivariate stepwise log-rank analysis on disease-free survival (DFS) and overall survival (OS).Results
This analysis included 128 women with early-stage TNBC. Clinical and histological characteristics are summarized below. After a median follow-up of 37 months 36 relapses and 19 deaths were observed. The 3-years recurrence rate was 30% (95%CI 22-40) in the whole population. For DFS, bad prognostic factors in univariate analysis were: large tumor size (T3-4), node involvement (N1-3), node capsular effraction, lymphovascular invasion (LVI) and high grade (SBR 2-3). Multivariate analysis identified tumor size (T3-4) (HR 3.70, 95%CI 1.61-8.52) and LVI (HR 2.87, 95%CI 1.39-5.93) as independent factors. The 3-years recurrence rate remained high (20%, 95%CI 10-34) in patients with two good prognostic factors (T0-2 and no LVI). For OS, bad prognostic factors significant in univariate and multivariate analysis were: node capsular effraction (HR 3.57, 95%CI 1.17-10.92) and LVI (HR 3.43, 95%CI 1.18-9.92).Conclusions
In this early-stage TNBC series, LVI was a bad prognostic factor of relapse and death. However, the 3-years recurrence rate remained high in patients with good prognostic features. Therefore, new biomarkers are mandatory for a better stratification of this heterogeneous population.
Clinical and histological characteristics
|N (128pts) %|
|Median age (yrs)||56||range 22-88|
|Invasive ductal carcinoma||123||96|
|Invasive lobular carcinoma||5||4|
|Node capsular effraction|
|Tumor grade (SBR)|
|Lymphovascular invasion (LVI)|
*Due to neoaduvant chemotherapy **Due to small biopsies.Disclosure
S. Haouas: Grant from Association pour la Recherche en Thérapeutiques Innovantes en Cancérologie (ARTIC).
All other authors have declared no conflicts of interest.